Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. IPX
IPX logo

IPX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Iperionx Ltd (IPX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
49.610
1 Day change
-1.29%
52 Week Range
61.450
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Based on the data provided, Iperionx Ltd (IPX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows bullish technical indicators, positive news catalysts related to rare earth metal production and U.S. government support, and has a strong probability of price appreciation in the next month. Despite the lack of financial data and options sentiment, the positive catalysts outweigh the negatives, making this a favorable investment opportunity.

Technical Analysis

The MACD is positive and contracting, indicating a bullish trend. The RSI is neutral at 55.375, suggesting no overbought or oversold conditions. The moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading above the pivot level of 46.364, with resistance levels at 50.18 and 52.538.

Positive Catalysts

  • U.S. government funding and support for rare earth metal production.

  • REalloys' partnerships to secure a complete supply chain and reduce reliance on China.

  • U.S. Department of Defense regulations prohibiting Chinese-origin rare earth materials, boosting domestic production and investment.

Neutral/Negative Catalysts

  • Lack of financial data for the latest quarter.

  • No significant hedge fund or insider trading trends observed.

Financial Performance

No financial data available for assessment.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data provided.

Wall Street analysts forecast IPX stock price to rise
2 Analyst Rating
Wall Street analysts forecast IPX stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 50.260
sliders
Low
74
Averages
74
High
74
Current: 50.260
sliders
Low
74
Averages
74
High
74
Spruce Point Capital
downgrade
AI Analysis
2025-11-12
Reason
Spruce Point Capital
Price Target
AI Analysis
2025-11-12
downgrade
Reason
Spruce Point Capital, in a research note, said that after conducting a forensic review of IperionX and its ambitions of becoming a vertically integrated producer of titanium powders and products, the firm believes that investor expectations are too high, and it faces significant challenges in commercial efforts that may not be fully reflected in its valuation. Spruce Point also expressed concerns with the accuracy of its financial reporting and says it does not believe the end markets to be attractive or that its highly promoted HAMR process is likely to "revolutionize" the industry. Based on the firm's analysis, Spruce Point advises investors to exercise caution because the shares may be significantly overvalued, with potential downside risk of 70% - 95% under certain scenarios. Reference Link
Roth Capital
Buy
maintain
$64 -> $74
2025-10-01
Reason
Roth Capital
Price Target
$64 -> $74
2025-10-01
maintain
Buy
Reason
Roth Capital raised the firm's price target on IperionX to $74 from $64 and keeps a Buy rating on the shares. The firm cites the company's FY25 results and the receipt of additional government funding as part of its existing $47.1M award, the analyst tells investors in a research note. Roth adds that its higher price target reflects lower future dilution assumptions and a higher multiple on 2029 EBITDA.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IPX
Unlock Now

People Also Watch